Figure 2.

Pre‐emptive (PE) anti‐B‐cell immunotherapy for EBV. To monitor patients at risk for EBV PTLD, EBV DNA load was measured on a regular basis. At a level of 1000 copies/mL, the patients were recalled to the hospital, and PE therapy with rituximab (anti‐CD20 therapy) was initiated. Monitoring was performed five times a week, until the EBV DNA level was twice below the limit of detection of the assay (50 copies/mL). If the signal did not decrease rapidly (or an increase was observed), a second infusion of rituximab or an infusion of donor lymphocytes (DLI) was given (see data represented by a thick line). The initiation of PE therapy is represented as day 0. Each line represents an individual patient.